Verified July 2026 · Cited to primary sources
Peptides marketed for skin, collagen, and anti-aging, graded by human evidence and legal status. The strongest skin evidence belongs to topical copper peptides (GHK-Cu), a legal cosmetic lane covered separately. The injectables here are far less proven.
Evidence for this goal
Among injectable options, KPV and Epitalon are both Grade D, with no human efficacy trials. The evidence-backed skin route is topical GHK-Cu (Grade B for topical/cosmetic use), which is legal as a cosmetic and doesn't require injecting anything. We'd point most people there, not to a research injectable.
How to read this comparison
Compounds are listed alphabetically, not ranked for this goal. The overall grade reflects the evidence described in each record. Evidence for one condition, population or product form does not establish benefit for every use. Affiliate availability never changes a grade.
A historical FDA survey of compounded drugs found 31% failed standard potency testing. What is actually in the vial is a separate question from whether the compound works, and a rubric like this exists to keep the two apart. See the full A to F methodology →
Evidence scope: There are small randomized, placebo-controlled human topical studies, which is why this earns a C rather than a D. A 2013 randomized placebo-controlled study in Chinese subjects reported reduced periorbital wrinkle depth and roughness versus placebo (subjective anti-wrinkle efficacy around 49 percent vs 0 percent placebo). A later small double-blind crow's-feet trial found palmitoyl pentapeptide-4 outperformed acetyl hexapeptide-3, with objective instrument measures not reaching significance. So the human evidence is real but from small studies with modest, sometimes non-significant objective effects. Grade C reflects small human topical studies showing a genuine but limited benefit.
Sources: Wang Y, et al. The anti-wrinkle efficacy of synthetic hexapeptide (Argireline) in Chinese subjects: a randomized, placebo-controlled study. J Cosmet Laser Ther, 2013 (PMID 23607739). · Aruan RR, et al. Double-blind, Randomized Trial on Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet. J Clin Aesthet Dermatol, 2023. · Acetyl Hexapeptide-8 in Cosmeceuticals: A Review of Skin Permeability and Efficacy. Int J Mol Sci, 2025.
Acetyl hexapeptide-8 mimics the N-terminal end of SNAP-25, a protein in the SNARE complex that muscle needs to release acetylcholine at the neuromuscular junction. By competing with SNAP-25, it is proposed to modestly dampen muscle contraction and so soften expression lines, a topical echo of what botulinum toxin does by injection. The big practical caveat is delivery: the peptide is large and hydrophilic, penetrates the stratum corneum poorly, and much of what is applied never reaches the nerve endings in the dermis. That penetration ceiling is the main reason topical effects stay modest.
Fine to use, just keep expectations honest. Argireline is a legal, safe, inexpensive cosmetic peptide with small placebo-controlled studies behind it, but the effect is a subtle softening of fine expression lines, held back by poor skin penetration. It is not topical Botox and will not match an injection. If you want it, treat it as a gentle add-on, not the centerpiece of a routine.
See the evidence →Evidence scope: Grade D: small, low-quality Russian human studies plus animal work, no rigorous RCT (rule 5/4 boundary: evidence quality too low to clear the human-trial bar, so it sits at D).
Sources: FDA PCAC July 23-24, 2026 meeting (docket, July 24) · Federal Register FDA-2025-N-6895 (April 2026 503A reclassification)
Claimed to activate telomerase and regulate melatonin/circadian and pineal function. Marketed for longevity and anti-aging.
Epitalon is not FDA-approved and remains under FDA review. On July 24, 2026 the PCAC panel voted 7 to 4 (1 abstention) to recommend adding it to the 503A list for insomnia, but that is advisory and the FDA has not acted. Human evidence is Grade D: the longevity and anti-aging claims rest on small, low-quality Russian studies.
See the evidence →Evidence scope: Grade B for TOPICAL/cosmetic use. GHK-Cu has real, decades-long human topical evidence (Pickart's tissue-remodeling work plus controlled cosmetic studies on aging skin) but is not an FDA-approved drug (rule 3 boundary: real but limited human data, no drug approval). Important split: INJECTED/systemic GHK-Cu has only preclinical data and no legal supervised route, so that form is Grade D and unapproved. This record grades the topical cosmetic lane, which is the legal, evidenced one.
Sources: Pickart, J Biomater Sci Polym Ed 2008: the human tripeptide GHK and tissue remodeling (review) · FDA 503A bulks list (injectable GHK-Cu removed from Category 2; topical cosmetic use is a separate legal channel)
A copper-binding tripeptide that stimulates collagen and elastin synthesis, activates fibroblasts, and supports wound repair. Its strongest evidence is topical, on skin.
GHK-Cu (copper peptides) is legal as a topical cosmetic, and for skin its human evidence is Grade B: real topical/cosmetic data, no drug approval. Injected GHK-Cu is a different, unapproved story (Grade D, no legal route). For skin or hair, the topical serum is the evidenced, legal choice. You don't need to inject anything.
See the evidence →Evidence scope: Grade D: preclinical only (cell and animal colitis models), no published human RCT (rule 5 fired).
Sources: FDA PCAC July 23-24, 2026 meeting (docket) · RAPS: FDA advisory committee backs controversial peptides (July 23, 2026 vote coverage) · Federal Register FDA-2025-N-6895 (April 2026 503A reclassification)
Anti-inflammatory tripeptide that suppresses NF-κB and pro-inflammatory signaling. Studied for gut and skin inflammation.
KPV is not FDA-approved and is not yet legal to compound. On July 23, 2026 the FDA's PCAC panel voted 8 to 6 (1 abstention) to recommend adding it to the 503A list for wound healing and inflammatory conditions, overriding the FDA's own scientists, but the FDA still decides and has not acted. Human evidence stays Grade D: cell and animal anti-inflammatory data only, no human trials.
See the evidence →Evidence scope: This has the strongest cosmetic evidence base on the list, but it is still small topical studies, so it lands at C. Robinson's 2005 double-blind, placebo-controlled split-face trial in 93 women found significant improvement in wrinkles and fine lines versus vehicle at just 3 ppm, with tolerability comparable to placebo and without retinoid-style irritation. A later small double-blind crow's-feet trial found palmitoyl pentapeptide-4 beat acetyl hexapeptide-3, though objective instrument measures did not reach significance. Cell studies confirm dose-dependent collagen stimulation. Grade C reflects genuine but modest human topical evidence.
Sources: Robinson LR, et al. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci, 2005 (PMID 18492182). · Aruan RR, et al. Double-blind, Randomized Trial on Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet. J Clin Aesthet Dermatol, 2023.
Matrixyl is palmitoyl-KTTKS: the pentapeptide KTTKS, a fragment of type I collagen, joined to a palmitic-acid tail that helps it cross the skin barrier. KTTKS acts as a matrikine, a signaling fragment that tells dermal fibroblasts to ramp up production of type I and type III collagen and fibronectin, essentially mimicking the feedback signal of collagen breakdown to prompt new matrix synthesis. The palmitoyl tail improves lipophilicity and skin penetration, which is why it tends to outperform non-lipidated peptides like argireline in head-to-head cosmetic studies. Unlike argireline it works by rebuilding matrix rather than relaxing muscle.
The one cosmetic peptide here worth a spot in a routine. Matrixyl has the best human evidence of the group: real split-face trials show a modest reduction in fine lines with retinoid-like benefit and none of the irritation. It will not remodel deep wrinkles or replace a retinoid, but as a gentle, well-tolerated add-on, especially for people who cannot tolerate retinoids, it is a defensible pick.
See the evidence →Evidence scope: Afamelanotide is FDA-approved (October 2019, Scenesse, NDA 210797) to increase pain-free light exposure in adults with erythropoietic protoporphyria, backed by two multicenter randomized, double-blind, placebo-controlled trials published in the New England Journal of Medicine (2015). That is Grade A evidence for its approved indication. Note: the evidence and approval cover the medical EPP use only. The tanning use that most people associate with melanotan-1 is NOT approved, NOT studied for safety in that context, and is a separate gray-market practice.
Sources: Langendonk et al., Afamelanotide for Erythropoietic Protoporphyria, NEJM 2015 (pivotal RCTs, PMID 26132941) · FDA prescribing label: SCENESSE (afamelanotide) implant (DailyMed) · NCBI LiverTox: Afamelanotide (confirms 2019 FDA approval, MC1R agonist)
Afamelanotide is a synthetic, more stable analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It is a selective agonist at the melanocortin-1 receptor (MC1R) on melanocytes, driving synthesis of eumelanin in the skin independent of UV exposure. The extra eumelanin is photoprotective, which is the basis of its approved use.
Legitimate, best-in-class evidence for one narrow job: photoprotection in erythropoietic protoporphyria, where it is FDA-approved. For that use, Grade A. For the tanning use most people are actually asking about, you are buying an unapproved gray-market peptide with real melanoma-surveillance concerns and none of the approval-grade safety backing. Do not conflate the two.
See the evidence →Evidence scope: Grade D: no FDA approval and no adequate efficacy RCT, only small early studies, sold illegally with documented harms (decision-tree rule 5 fired: no published human efficacy RCT). Do not confuse it with afamelanotide (Melanotan-1 / Scenesse), a different, more receptor-selective peptide that IS FDA-approved (2019) for a rare condition (erythropoietic protoporphyria). Melanotan-2 is not that drug and is not approved for anything.
Sources: FDA Warning Letter (Melanocorp, Inc.): Melanotan II marketed as an unapproved new drug for injectable tanning · Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report (PMC), documented pigmentary/systemic effects · FDA 503A bulks list (Melanotan II removed from Category 2; no legal compounding route) · Afamelanotide (SCENESSE), the FDA-APPROVED, distinct MC1R-selective peptide, for comparison · Cleveland Clinic, Why You Should Never Use Nasal Tanning Spray, with dermatologist Allison Vidimos, RPh, MD: melanotan II still requires UV exposure to work, and is illegal to sell in all fifty US states, the United Kingdom and Australia · Forbes, Tanning Influencers Push Barbie Peptide. Here Are Risks Of Melanotan, by Bruce Y. Lee, MD, MBA, August 7, 2026: melanoma reports, rhabdomyolysis with kidney failure, renal infarction, and a documented twenty two hour priapism
A non-selective melanocortin-receptor agonist that stimulates melanocytes to produce pigment (tanning), with off-target effects on appetite, sexual arousal and the cardiovascular system because it hits multiple melanocortin receptors.
Melanotan-2 (MT-2) is an unapproved "tanning" peptide with documented serious harms: melanoma and mole changes, priapism, nausea, blood-pressure changes and rhabdomyolysis have all been reported. Human evidence is Grade D and the safety flag is red. It is not the same as FDA-approved afamelanotide (Scenesse). There is no safe or legal way to buy it, and we do not recommend it.
See the evidence →| Peptide | Overall grade | Legal & safety | Typical cost | Verdict | |
|---|---|---|---|---|---|
| Argireline (Acetyl Hexapeptide-8) The peptide marketed as topical Botox. It does have small placebo-controlled human studies behind it, but the honest read is a modest softening of fine lines, nowhere near what an injection does. | Grade C | See evidenceSee the evidence for Argireline (Acetyl Hexapeptide-8) | |||
| Epitalon A longevity and anti-aging peptide built on small, low-quality Russian studies. The claims far outrun the evidence. | Grade D | See evidenceSee the evidence for Epitalon | |||
| GHK-Cu The copper peptide behind decades of skincare. Real human topical/cosmetic evidence for skin, but injected versions are a different, unproven story. | Grade B | See evidenceSee the evidence for GHK-Cu | |||
| KPV An anti-inflammatory tripeptide studied for gut and skin inflammation. Promising in cells and animals, untested in humans. | Grade D | See evidenceSee the evidence for KPV | |||
| Matrixyl (Palmitoyl Pentapeptide-4) The best-supported cosmetic peptide here. Real split-face human trials show a modest, retinol-adjacent reduction in fine lines, and it is gentle. Just do not expect a dramatic change. | Grade C | See evidenceSee the evidence for Matrixyl (Palmitoyl Pentapeptide-4) | |||
| Melanotan-1 (Afamelanotide / Scenesse) The one melanotan that is actually an FDA-approved drug. As Scenesse, afamelanotide is a prescription implant for a rare light-sensitivity disorder, not the gray-market tanning peptide people buy online. | Grade A | See evidenceSee the evidence for Melanotan-1 (Afamelanotide / Scenesse) | |||
| Melanotan-2 (MT-2) The tanning peptide sold under the nicknames "Barbie peptide" and "Barbie drug", unapproved, with documented serious harms. Melanoma and mole changes, priapism, nausea, and rhabdomyolysis have all been reported. This is a safety page, not a recommendation. | Grade D | See evidenceSee the evidence for Melanotan-2 (MT-2) |
Reading this table: Grades refer to each compound's stated evidence scope, not every use in this category. Legal status and Safety are separate badges; Verdict is the compound summary. Affiliate availability never changes a grade. Full methodology.
It is melanotan-2. A synthetic melanocortin-receptor agonist, sold as a subcutaneous injection and as a nasal tanning spray, approved by no regulator, and graded D here with a red safety flag. There is no legal supervised US route to it. On this hub it is the entry we would tell you to avoid outright rather than rank.
The distinction that almost every write-up loses is between melanotan-1 and melanotan-2, and it is worth getting right because one of them is a real approved medicine. Melanotan-1 is afamelanotide, sold as Scenesse, FDA-approved in 2019 and selective for the MC1R receptor. It is approved for erythropoietic protoporphyria, a rare disorder in which sunlight causes severe pain, and for nothing else. Melanotan-2 is a shorter, non-selective peptide that hits several melanocortin receptors at once, which is why it also drives appetite, sexual and cardiovascular effects, and it holds no approval anywhere. Both have a graded page here. When coverage says an approval exists, it is talking about the first one, and that approval is not evidence for the second.
The finding worth carrying off this page is what the product actually does. Melanotan-2 does not replace the sun, it recruits it. Cleveland Clinic dermatologist Allison Vidimos puts it plainly: the peptide stimulates melanin but does not pigment skin on its own, and it still requires exposure to ultraviolet light in order to work. So a compound sold as the safe way to skip sun damage only produces a tan by sending the user into more sun, faster, with more moles. The same article notes melanotan-2 is illegal to sell in all fifty US states and in the United Kingdom and Australia.
The nasal spray is the newer and the more casual route, and it is not the gentler one. The lining of the nose is mucosa rather than skin, and mucosa does not offer the same barrier, so an inhaled dose reaches the bloodstream faster than a topical would. The documented harms are not mild either. Case reports link melanotan-2 to dysplastic moles and melanoma, and physician-authored coverage in August 2026 catalogued rhabdomyolysis severe enough to cause kidney failure, renal infarction, and a painful erection lasting twenty two hours that needed emergency care.
Sources, each read first-hand: Cleveland Clinic, Why You Should Never Use Nasal Tanning Spray, with dermatologist Allison Vidimos, RPh, MD. Also: Forbes, Tanning Influencers Push Barbie Peptide. Here Are Risks Of Melanotan, by Bruce Y. Lee, MD, MBA, August 7, 2026.
FAQ
The strongest skin evidence belongs to topical copper peptides (GHK-Cu), which are legal as a cosmetic and don't require injecting anything. Among the injectable options here, KPV and Epitalon are both Grade D, with no human efficacy trials, so we'd point most people to a topical copper-peptide serum instead.
There is no reliable human evidence that Epitalon reverses aging or extends lifespan. The anti-aging and telomerase claims come from small, low-quality Russian studies and animal work, which lands it at Grade D on our scale.
The injectable skin peptides here (KPV, Epitalon) have little to no human safety data and no legal supervised US route. FDA testing has found many online and compounded peptides are mislabeled or contaminated, which is why we favor legal topical copper-peptide cosmetics for skin.
It is melanotan-2, an unapproved synthetic melanocortin agonist sold as an injection and as a nasal tanning spray. We grade it D with a red safety flag. It is not the same compound as melanotan-1 (afamelanotide, brand Scenesse), which the FDA did approve in 2019, but only for a rare light-sensitivity disorder and never for cosmetic tanning. Mainstream coverage runs the two names together constantly, and the difference is the whole answer: one is an approved drug for a rare disease, the other is not approved for anything.
Read the evidence
Before you buy anything
Other goals
The monthly peptide evidence brief.
What the research and the FDA actually say, in one short email a month. Unsubscribe anytime.
No spam. We never sell your email. Editorial policy.